PortfoliosLab logoPortfoliosLab logo
SPRO vs. BNTC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SPRO vs. BNTC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SPRO achieves a -7.73% return, which is significantly lower than BNTC's -4.38% return.


SPRO

1D
-2.71%
1M
-22.10%
YTD
-7.73%
6M
-7.73%
1Y
-26.62%
3Y*
10.35%
5Y*
-32.21%
10Y*

BNTC

1D
4.72%
1M
14.69%
YTD
-4.38%
6M
-0.62%
1Y
-11.60%
3Y*
56.15%
5Y*
-28.76%
10Y*
-27.78%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SPRO vs. BNTC - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SPRO
Spero Therapeutics, Inc.
-7.73%126.21%-29.93%-15.03%-89.19%-17.43%101.66%56.34%-47.66%-11.32%
BNTC
Benitec Biopharma Inc.
-4.38%6.65%291.02%11.76%-93.51%-12.67%-60.78%-66.00%-49.27%4.70%

Correlation

The correlation between SPRO and BNTC is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Nov 2, 2017

0.12

The correlation between SPRO and BNTC shifts across timeframes, from 0.12 (all time) to 0.23 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

SPRO:

$123.16M

BNTC:

$636.09M

EPS

SPRO:

$0.39

BNTC:

-$1.13

PS Ratio

SPRO:

2.25

BNTC:

1.00K

PB Ratio

SPRO:

2.33

BNTC:

3.47

Total Revenue (TTM)

SPRO:

$54.77M

BNTC:

$556.00K

Gross Profit (TTM)

SPRO:

$54.51M

BNTC:

$40.00K

EBITDA (TTM)

SPRO:

$12.49M

BNTC:

-$55.66M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SPRO vs. BNTC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRO
SPRO Risk / Return Rank: 2121
Overall Rank
SPRO Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
SPRO Sortino Ratio Rank: 2525
Sortino Ratio Rank
SPRO Omega Ratio Rank: 2424
Omega Ratio Rank
SPRO Calmar Ratio Rank: 1717
Calmar Ratio Rank
SPRO Martin Ratio Rank: 1717
Martin Ratio Rank

BNTC
BNTC Risk / Return Rank: 3535
Overall Rank
BNTC Sharpe Ratio Rank: 3535
Sharpe Ratio Rank
BNTC Sortino Ratio Rank: 3535
Sortino Ratio Rank
BNTC Omega Ratio Rank: 3535
Omega Ratio Rank
BNTC Calmar Ratio Rank: 3333
Calmar Ratio Rank
BNTC Martin Ratio Rank: 3434
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRO vs. BNTC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


SPROBNTCDifference
Sharpe ratioReturn per unit of total volatility

-0.26

Sortino ratioReturn per unit of downside risk

-0.44

Omega ratioGain probability vs. loss probability

0.96

1.02

-0.06

Calmar ratioReturn relative to maximum drawdown

-0.67

-0.30

-0.37

Martin ratioReturn relative to average drawdown

-1.15

-0.49

-0.67

SPRO vs. BNTC - Sharpe Ratio Comparison

The current SPRO Sharpe Ratio is -0.46, which is lower than the BNTC Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of SPRO and BNTC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

SPRO vs. BNTC - Drawdown Comparison

The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum BNTC drawdown of -99.92%. Use the drawdown chart below to compare losses from any high point for SPRO and BNTC.


Loading charts...

Drawdown Indicators


SPROBNTCDifference

Max Drawdown

Largest peak-to-trough decline

-97.46%

-99.92%

+2.46%

Max Drawdown (1Y)

Largest decline over 1 year

-39.80%

-39.10%

-0.70%

Max Drawdown (3Y)

Largest decline over 3 years

-68.89%

-68.46%

-0.43%

Max Drawdown (5Y)

Largest decline over 5 years

-97.13%

-97.41%

+0.28%

Max Drawdown (10Y)

Largest decline over 10 years

-99.82%

Current Drawdown

Current decline from peak

-90.26%

-99.44%

+9.18%

Average Drawdown

Average peak-to-trough decline

-62.44%

-88.42%

+25.98%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.13%

23.84%

-0.71%

Volatility

SPRO vs. BNTC - Volatility Comparison

Spero Therapeutics, Inc. (SPRO) has a higher volatility of 33.09% compared to Benitec Biopharma Inc. (BNTC) at 16.13%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than BNTC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SPROBNTCDifference

Volatility (1M)

Calculated over the trailing 1-month period

33.09%

16.13%

+16.96%

Volatility (6M)

Calculated over the trailing 6-month period

45.23%

38.20%

+7.03%

Volatility (1Y)

Calculated over the trailing 1-year period

58.61%

60.82%

-2.21%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

152.14%

101.70%

+50.44%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

124.88%

132.10%

-7.22%

Dividends

SPRO vs. BNTC - Dividend Comparison

Neither SPRO nor BNTC has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018
BNTC
Benitec Biopharma Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.20%
SPRO
Spero Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

SPRO vs. BNTC - Financials Comparison

This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Benitec Biopharma Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
258.00K
0
(SPRO) Total Revenue
(BNTC) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SPRO and BNTC have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SPRO has higher volatility (33.09%) compared to BNTC (16.13%). In terms of maximum drawdown, SPRO dropped -97.46% vs BNTC's -99.92%.

BNTC currently has the higher Sharpe Ratio (-0.19 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SPRO and BNTC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer